Intellia Therapeutics (NTLA) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Intellia Therapeutics (NTLA) over the last 5 years, with Sep 2025 value amounting to -$0.92.
- Intellia Therapeutics' EPS (Weighted Average and Diluted) rose 31.34% to -$0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.26, marking a year-over-year increase of 21.69%. This contributed to the annual value of -$5.25 for FY2024, which is 3.14% up from last year.
- Intellia Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.92 in Q3 2025, which was up 6.12% from -$0.98 recorded in Q2 2025.
- Over the past 5 years, Intellia Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.69 during Q2 2021, and registered a low of -$1.96 during Q1 2022.
- For the 3-year period, Intellia Therapeutics' EPS (Weighted Average and Diluted) averaged around -$1.24, with its median value being -$1.26 (2024).
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first crashed by 92.75% in 2022, then skyrocketed by 40.31% in 2023.
- Quarterly analysis of 5 years shows Intellia Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.10 in 2021, then declined by 25.45% to -$1.38 in 2022, then fell by 5.80% to -$1.46 in 2023, then increased by 13.70% to -$1.26 in 2024, then skyrocketed by 31.34% to -$0.92 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.92 for Q3 2025, versus -$0.98 for Q2 2025 and -$1.10 for Q1 2025.